FILTER

FILTERED INTERVIEW RESULTS

Jay Shukla

PRESIDENT & CEO, NIVAGEN PHARMACEUTICALS, INC.
Nivagen Pharmaceuticals provides complete research, analytical formulation development, and regulatory support.

Dr. Jagadeesh Babu Rangisetty

FOUNDER & CEO, BIOPHORE
Biophore explains how it is expanding productions of different APIs to ensure both quality and supply chain security.

James Gale

CEO, SIGNET HEALTHCARE PARTNERS
Signet Healthcare Partners speaks to GBR about how it is evolving its’ investment portfolio in life sciences.

Emer Leahy

PRESIDENT AND CEO, PSYCHOGENICS
PsychoGenics explains how CNS is attracting unprecedented attention and how its AI-driven phenotypic discovery platforms can help to deliver cures.

Keith Crandell

CO-FOUNDER & MANAGING DIRECTOR, ARCH VENTURE PARTNERS
ARCH Venture Partners explains the secrets to successful innovation in todays’ life sciences.

Daniel J. O’Connor

PRESIDENT & CEO, ONCOSEC MEDICAL INCORPORATED
OnoSec Medical explains how treating cancers with a plasmid-based approach can avoid side effects and work on immunologically cold tumors.

Jorge Nogueira

CEO, DIPHARMA FRANCIS
Dipharma speaks to GBR of how it is adapting to market trends and expanding its geography.

Peter Meath

CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, MIDDLE MARKET, J.P. MORGAN COMMERCIAL BANKING
"While the underlying business model for life sciences companies hasn’t changed as a result of our current environment, we’re seeing that increased capital has been made available to those seeking funding. This makes it an incredibly promising time for the sector."

Timothy J. Miller

PRESIDENT & CEO, FORGE BIOLOGICS
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."

Lesley Millar-Nicholson

DIRECTOR, MIT TECHNOLOGY LICENSING OFFICE
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Latin America Petrochemicals and Chemicals 2024 - Digital Interactive

The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.

PARTNER EVENTS